Sign In

Patricia Schroeder

Senior Director, Modeling and Simulation and Development Project Leader at FORMA Therapeutics, Inc.

Professional Background

Patricia Schroeder is an esteemed expert in pharmacokinetics and drug metabolism, with a proven track record in drug development and pharmaceutical sciences. Currently, she serves as the Senior Director of Modeling and Simulation at FORMA Therapeutics, Inc., where she leads initiatives in advancing pharmacokinetic and pharmacodynamic research. Under her guidance, the team defines innovative strategies to support new drug candidates, enhancing the overall understanding of drug behavior within the body.

Before her tenure at FORMA Therapeutics, Patricia held a significant position as the Director of Modeling and Simulation at the same organization. Here, she played a pivotal role in streamlining modeling processes that contribute to effective drug development workflows. Her impressive career includes prior leadership roles at prestigious pharmaceutical companies such as Biogen, where she served as a Principal Scientist, contributing to cutting-edge research in drug efficacy and safety.

Patricia's expertise began to flourish during her time at EMD Serono, Inc., where she served as the Modeling and Simulation Project Representative. This role demanded a combination of technical knowledge and strategic foresight, both of which Patricia exhibited, successfully collaborating across teams to enrich project outcomes. Further, her career encompassed significant time spent at AstraZeneca R&D, where she held multiple esteemed positions including Principal Scientist and Sr. Scientist PK/PD. In these roles, she was instrumental in the development and optimization of drug candidates, showcasing her strong capability in pharmacokinetics and pharmacodynamics.

Patricia's foundational years in the industry began at Boehringer Ingelheim, where she worked as a Research Scientist. It was in this capacity she honed her knowledge and skills in the complexities of drug absorption, distribution, metabolism, and excretion (ADME), providing a basis for her future successes.

Education and Achievements

Patricia Schroeder’s academic background is commendable; she holds a Ph.D. in Pharmacokinetics and Drug Metabolism from the University of Manitoba. Her rigorous training has made her well-equipped to tackle challenging questions in drug development, especially in the realms of pharmacokinetics and pharmacodynamics. Her involvement in various research projects during her academic journey laid the groundwork for her impressive career in the pharmaceutical sector.

Her publication records and participation in numerous prestigious conferences as a speaker and panelist underline her commitment to advancing the field of pharmacokinetics and drug metabolism. Patricia is consistently recognized by her peers for her substantial contributions to the scientific community.

Achievements

Throughout her career, Patricia Schroeder has made notable contributions that have significantly impacted the field of pharmaceutical sciences. Among her many achievements, she has successfully led teams to develop innovative modeling strategies that improve the understanding of drug action and safety. Furthermore, her leadership has not only yielded successful drug candidates but has also fostered professional growth among her team members.

Patricia's work is characterized by a blend of scientific rigor and strategic management. Her ability to translate complex scientific data into actionable insights has positioned her as a thought leader in the area of drug modeling and simulation. Her dedication to excellence continues to inspire those around her, and she remains a sought-after expert in her field.

Related Questions

How did Patricia Schroeder develop her expertise in pharmacokinetics and drug metabolism?
What are some of the key contributions Patricia Schroeder made while working at AstraZeneca R&D?
How has Patricia Schroeder's education at the University of Manitoba influenced her career in pharmaceuticals?
What innovative strategies has Patricia Schroeder implemented in her role at FORMA Therapeutics?
In what ways has Patricia Schroeder contributed to advancing drug development processes during her career?
P
Add to my network

Location

Greater Boston